Dong-A ST

Diversified pharma

170900 · KOSPI · South Korea

Public Market Listing

170900KOSPI

KOSPI primary exchange listing

Live quotes, historical charts, and market capitalization for Dong-A ST are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(9 total)
9Total Assets
1Approved
1Phase 3 / Filed
7Phase 1–2 / Early
8Diseases
Quick filter:
Showing 9 of 9 assets
Target & Modality
Approved
IL-12 p40Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease
Evogliptin(Suganon)
Phase 3
DPP-4Small molecule
Type 2 Diabetes
Udenafil(Zydena)
Phase 2/3
PDE5Small molecule
Pulmonary Arterial Hypertension
Phase 2
SGLT2Small molecule
Type 2 Diabetes
Phase 2
GPR119Small molecule
Type 2 DiabetesMASH / NASH
Phase 1
GLP-1/glucagon receptor (dual)Peptide
Obesity
Phase 1
—
Chronic Hepatitis B
Phase 1
DPP-4 / SGLT2 / AMPK pathway (triple)Small molecule
Type 2 Diabetes
Preclinical / Unstaged
DPP-4 / SGLT2 (combination)Small molecule
Type 2 Diabetes

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
DA-2811Phase 2Diabete Mellitus
Est. primary completion 2026-12 · NCT07239440 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3————report ↗